Thermo Fisher Scientific has finalized the acquisition of Clario Holdings, a Philadelphia-based clinical trial data provider, for $8.9 billion. This significant deal consolidates a key player in the clinical data space, bringing Clario's expertise directly under Thermo Fisher's laboratory products and biopharma services segment. The transaction, led by a consortium of private equity firms including Astorg, Nordic Capital, Novo Holdings, and Cinven, marks a major strategic move for the laboratory giant. Thermo Fisher now gains direct access to Clario's proprietary data and analytics capabilities, enhancing its offerings to pharmaceutical and biotech clients. The $8.9bn price tag underscores the premium placed on specialized clinical data assets within the life sciences sector.